Very negotiable depending on experience: Singular Talent: Business Development role in AI driven drug discovery - help to drive the medicines of tomorrow with cutting-edge technology..... Oxford, Oxfordshire (GB)

Notice NOT-AI-20-066 from the NIH Guide for Grants and Contracts

Notice NOT-NS-20-089 from the NIH Guide for Grants and Contracts

Notice NOT-AI-20-065 from the NIH Guide for Grants and Contracts

Notice NOT-MD-20-025 from the NIH Guide for Grants and Contracts

Notice NOT-OD-20-160 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-NS-21-007 from the NIH Guide for Grants and Contracts. Accumulation of abnormal proteins such as alpha-synuclein or tau in the brains of patients with dementia tends to occur in specific brain structures (cells/circuits/regions), resulting in the unique clinical presentations that are characteristic of the different types of dementia. This funding opportunity announcement invites applications that seek to identify mechanisms responsible for this selective regional vulnerability to abnormal protein deposition in the brains of patients with Lewy Body Dementia or Frontotemporal Dementia.

Funding Opportunity RFA-CA-20-052 from the NIH Guide for Grants and Contracts. The purpose of this limited competition Funding Opportunity Announcement (FOA) is to continue support for the Childhood Cancer Survivor Study (CCSS) as a resource enabling broad studies on the long-term effects of cancer and its associated therapies on survivors of pediatric and adolescent cancers. CCSS is a multi-institutional collaborative project that supports a participant cohort of over 25,000 five-year survivors of childhood cancer diagnosed between 1970-1999 and over 5,000 sibling control subjects.

Funding Opportunity RFA-AG-21-021 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites early-stage physician and other health professional investigators with a commitment to aging and/or aging-related diseases to apply for this award to advance their research and leadership skills in their specialty and in the broader field of aging and geriatrics research. The National Institute on Aging (NIA) is pursuing this initiative to recruit early-stage investigators who have begun to establish research programs and who, through this award, will be ready to assume leadership roles in their field of expertise and will be poised to change theory, practice, and health outcomes related to the health of older individuals. Unlike other mentored K awards, candidates for this award must have received competitively awarded research support as a Program Director/Principal Investigator (PD/PI) at the faculty level or have otherwise leveraged faculty-level research support to develop an independent line of research. They must show evidence of leadership in the clinical or research domain.

Funding Opportunity PAR-20-284 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) entitled "Innovative Research in Cancer Nanotechnology (IRCN)" encourages applications promoting transformative discoveries in cancer biology and/or oncology through the use of nanotechnology. Proposed projects should address major barriers in cancer biology and/or oncology using nanotechnology and should emphasize mechanistic studies toward fundamental understanding of nanomaterial and/or nanodevice interactions with biological systems. These studies should be performed in context of research concerning the delivery of nanoparticles and/or nano-devices to desired and intended cancer targets in vivo and/or characterization of detection and diagnostic devices in vitro. IRCN awards are expected to produce fundamental knowledge to aid future and more informed development of nanotechnology-based cancer interventions.

Experience areas of interest include single-cell transcriptomics, 4-C / Hi-C, medical image data analysis, genome assembly, variant or copy number variation…
From University of Wisconsin–Madison - Thu, 13 Aug 2020 00:57:17 GMT - View all Madison, WI jobs

Funding Opportunity RFA-OH-21-004 from the NIH Guide for Grants and Contracts. NIOSH supports exploratory and developmental research projects (R21) that address/mitigate/improve issues related to diagnostic or treatment uncertainty with respect to individuals, including enrolled World Trade Center (WTC) responders and certified-eligible WTC survivors, receiving monitoring and/or treatment under subtitle B, of the James Zadroga 9/11 health and Compensation Act (Public Law 111-347). NIOSH seeks to achieve a suitable mix of projects that help advance treatment and diagnostic effectiveness and the understanding of the health and well-being of the WTC Health Program members related to the September 2001 terrorist attacks.

Notice NOT-OD-20-163 from the NIH Guide for Grants and Contracts

Notice NOT-MH-20-072 from the NIH Guide for Grants and Contracts

Notice NOT-HL-20-806 from the NIH Guide for Grants and Contracts

Notice NOT-OH-20-007 from the NIH Guide for Grants and Contracts

Notice NOT-OH-20-006 from the NIH Guide for Grants and Contracts

Notice NOT-OD-20-162 from the NIH Guide for Grants and Contracts

Notice NOT-MD-20-026 from the NIH Guide for Grants and Contracts

Notice NOT-AI-20-067 from the NIH Guide for Grants and Contracts